Teladoc faces securities fraud investigation after cutting 2026 revenue guidance and stock plunges 38%.

Teladoc Health announced a lowered revenue forecast for 2026, citing challenges in its business model and pressures on its BetterHelp platform. Following this, its stock price dropped sharply by 38.32%. Pomerantz LLP has launched an investigation into whether Teladoc and its executives engaged in securities fraud or other illegal practices. Investors affected are encouraged to contact the law firm as the case develops.